Sequent Scientific

SeQuent Scientific shares gain 7% on merger update; check key details here

SeQuent Scientific and Viyash Lifesciences Private Limited announced through an exchange filing that the NCLT has approved the merger scheme between SeQuent and the Viyash group of companies.

Here's why Sequent Scientific shares dropped 6% in trade on Feb 11; details

The fall in Sequent Scientific share price came after the company reported a 58.5 per cent year-on-year (Y-o-Y) drop in profit at Rs 3.4 crore in Q3FY25

CCI clears merger of nine pharma entities with Sequent Scientific

The Competition Commission on Tuesday cleared the proposed amalgamation of nine entities with pharmaceutical firm Sequent Scientific Ltd (SSL). "The proposed combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity," CCI (Competition Commission of India) said in a release. SSL offers active pharmaceutical ingredients (APIs), finished dosage formulations, and analytical services for the animal health sector. Sequent Research Ltd (SRL), a wholly-owned subsidiary of SSL, is a contract research organisation. Viyash is a pharmaceutical company and through its subsidiaries is primarily engaged in the development, manufacture and sale of APIs and intermediates for human healthcare in India. Symed Labs, Appcure Labs, Vindhya Pharma (India) and Vandana Life Sciences are wholly-owned subsidiaries of Viyash while S V Labs is a

Carlyle-backed SeQuent, Viyash Life Sciences announce Rs 8,000 crore merger

Rs 8,000 crore merger will create one of the largest animal health companies in India

SeQuent Scientific jumps 18% after announcing merger with Viyash Life

The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle

Sequent Scientific stock hits 52-week high on WHO prequalification nod

The rise in the share price came after the company announced that it has received World Health Organisation (WHO) prequalification approval for Albendazole Active Pharmaceutical Ingredient (API).

Stocks to Watch today, Sep 15: Infosys, Airtel, BoM, GMM Pfaudler, Sequent

Stocks to watch on Friday, September 15, 2023: Buzzing today - Infosys secures a $1.5 bn global deal, GMM Pfaudler inks $7 mn acquisition and RBI places 15 NBFCs in top layer.

SeQuent Scientific rallies 15% on terminating pact to acquire Tineta Pharma

In November 2022, SeQuent had announced the acquisition of Tineta Pharma for Rs 218 crore but the said transaction has not materialised

Sequent Scientific tanks 17% on weak Q4; stock down 70% from 52-wk high

The company said the macro environment continues to be challenging due to volatility in costs and disruptions across supply chains.

Sequent Scientific slips 16% on disappointing June quarter results

Ebitda margins contracted 460 basis points to 11.2 per cent in Q1FY22 from 15.8 per cent in Q4FY21

Sequent Scientific up 9% on EUGMP nod for its tablets dosage form in Turkey

With over 120 product registrations, Sequent is the third-largest player in the Turkish ruminant market with a consolidated market share of around 10 per cent

Street rewards all but one of 12 companies that pruned share pledges

Sequent Scientific and Everyday Industries saw percentage shareholding pledged by promoters go down by over 44 per cent each and their shares rally by 68 per cent and 75 per cent, respectively

Carlyle Group to buy 74% in SeQuent Scientific for over Rs 1,500 crore

The transaction is being done through an equity purchase stake that values each share at Rs 86.

Sequent Scientific turns ex-stock split

The stock surged 9% to Rs 166 on the BSE after the stock turned ex-stock split today in the ratio of 1:5.